0 85

Cited 11 times in

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2

Authors
 Celine M. Vachon  ;  Daniel J. Schaid  ;  James N. Ingle  ;  D. Lawrence Wickerham  ;  Michiaki Kubo  ;  Taisei Mushiroda  ;  Matthew P. Goetz  ;  Erin E. Carlson  ;  Soonmyung Paik  ;  Norman Wolmark  ;  Yusuke Nakamura  ;  Liewei Wang  ;  Richard Weinshilboum  ;  Fergus J. Couch 
Citation
 Breast Cancer Research and Treatment, Vol.149(2) : 517-523, 2015 
Journal Title
 Breast Cancer Research and Treatment 
ISSN
 0167-6806 
Issue Date
2015
Abstract
Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case-control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 % increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (P intx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (P intx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/141411
DOI
10.1007/s10549-014-3175-4
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부)
Yonsei Authors
백순명(Paik, Soon Myung)
사서에게 알리기
  feedback
Full Text
http://link.springer.com/article/10.1007%2Fs10549-014-3175-4
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse